Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Skin Cancer01:30

Skin Cancer

5.7K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

[Study of electroreflectance spectrum and Franz-Keldysh effect at metal-GaAs interfaces].

Guang pu xue yu guang pu fen xi = Guang pu·2008
Same author

[Study on electro-degradation of new conjugated polymer PFO-BT15 light emitting diodes].

Guang pu xue yu guang pu fen xi = Guang pu·2008
Same author

Comparison of the curative effects of video assisted thoracoscopic anterior correction and small incision, thoracotomic anterior correction for idiopathic thoracic scoliosis.

Chinese medical journal·2008
Same author

Distribution and sources of mercury in soils from former industrialized urban areas of Beijing, China.

Environmental monitoring and assessment·2008
Same author

[Main flavonoids from Sophora flavescenes].

Yao xue xue bao = Acta pharmaceutica Sinica·2008
Same author

External validation and prediction employing the predictive squared correlation coefficient test set activity mean vs training set activity mean.

Journal of chemical information and modeling·2008

相关实验视频

Updated: Jan 13, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.5K

黑色素瘤:病原和向治疗

Yang Fu1, Jie Liu1, Zeming Mo1

  • 1Department of Medical Oncology Cancer Center West China Hospital Sichuan University Chengdu China.

MedComm
|January 6, 2026
PubMed
概括

向疗法和免疫疗法改变了黑色素瘤的治疗方法. MEK 抑制剂在NRAS突变黑色素瘤中表现有前途,解决了以前无法治疗的标.

科学领域:

  • 在瘤学瘤学.
  • 皮肤病学 皮肤病学
  • 分子生物学分子生物学

背景情况:

  • 黑色素瘤是一种具有NRAS,BRAF或NF1.1常见突变的侵袭性皮肤癌.
  • 针对性治疗为驱动器改变提供了显著的抗瘤活性.
  • 结合BRAF和MEK抑制剂改善了BRAF突变黑色素瘤的治疗结果.

研究的目的:

  • 审查黑色素瘤的分子病原和分类.
  • 探索当前和潜在的黑色素瘤治疗策略.
  • 专注于BRAF抑制剂,MEK抑制剂和免疫治疗的临床开发.

主要方法:

  • 关于分子病原和分类的文献综述.
  • 分析当前和新兴的治疗方法.
  • 专注于临床相关性和向疗法和免疫疗法的发展.

主要成果:

  • BRAF/MEK 抑制剂显著改善了 BRAF 突变黑色素瘤的预后.
  • MEK 抑制剂在NRAS突变黑色素瘤中表现出有效性,得到了tunlametinib 的批准.
  • 免疫检查点抑制剂已经重塑了晚期黑色素瘤治疗.
关键词:
这是一个BRAFBRAF.它们是NRAS和NRAS.免疫疗法 免疫疗法黑色素瘤是一种黑色素瘤.有针对性的治疗.

更多相关视频

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.8K
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.4K

相关实验视频

Last Updated: Jan 13, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.5K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.8K
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.4K

结论:

  • 黑色素瘤治疗已经通过向疗法和免疫疗法取得了进展.
  • NRAS突变黑色素瘤正在成为MEK抑制剂的向.
  • 在优化免疫疗法和针对黑色素瘤的向治疗方面仍然存在挑战.